26/06/2026
Gene therapy for babies is here, and itβs growing within Inherited Metabolic Disorders (IMDs).
Gene therapy is a medical approach that works by replacing or repairing faulty genes - giving the body the instructions it needs to function properly. For those living with Inherited Metabolic Disorders (IMDs), this science is already making a real difference, and it continues to move forward β this is positive news.
A new trial is now extending this progress to the youngest patients. The ornithine transcarbamylase (OTC).
OTC-HOPE trial is treating baby boys under 9 months old born with severe OTC deficiency. In newborn babies who have OTC, ammonia can build up in the blood to dangerous levels that, untreated, can be fatal. The trial delivers a single IV infusion carrying a working copy of the faulty gene directly to liver cells - and early results are promising: 5 out of 7 babies have had no dangerous ammonia crises since treatment.
Have you been following the OTC-HOPE trial? What are your thoughts? Drop a comment below
Find out more: https://otc-hope.com/